a. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2.
|
|
- Mae Ferguson
- 6 years ago
- Views:
Transcription
1 AND QUANTITATIVE PRECISION (SAMPLE UR-01, 2017) Background and Plan of Analysis Sample UR-01 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony count, to perform the identification of the organism, and to test the organism by routinely used antimicrobial susceptibility testing (AST) method/product. The sample contained an Escherichia coli strain (ATCC 25922), a quality control (QC) organism commonly applied by AST quality assurance procedures for disk diffusion (DD) or dilution MIC methods. 1-4 The E. coli is pan-susceptible to all frequently utilized Gram-negative-active antimicrobial agents. The use of this QC organism in an AST proficiency challenge provides the opportunity to analyze survey results for recognizing significant activity of antimicrobials against a susceptible strain. Furthermore, participant laboratories were requested to forward an additional response form with quantitative results (inhibitory zone diameters for DD; MICs for dilution tests), as well as the AST interpretive category criteria used to define susceptibility or resistance. 3-5 The overall response statistics included 16,610 potentially gradable category results; a total of 99.3% (16,496) were reported as susceptible. Among these over 1,100 laboratories, 379 participants forwarded quantitative AST results including 35.4 and 41.1% for MIC and DD test users, respectively (Tables 1-6). The interpretive category criteria utilized by each type of test/device applied are tabulated in Table 1. The breakpoint category criteria of the Clinical and Laboratory Standards Institute (CLSI) were most often used at 66.2% of laboratories overall (range, %); and USA-FDA breakpoints were applied by 19.0% (range, %) of participants. 3 Non-USA or unlisted/unknown criteria were cited by 14.8% of API Survey respondents (Table 1). 4,5 Table 1. API Survey subscriber use of antimicrobial susceptibility breakpoint organization criteria 3-5 for sample UR-01 (2017), by listed AST method or commercial product applied (379 responses). a AST breakpoint organizations AST method used by API participant (%): Disk Diffusion (DD) BD Phoenix MicroScan Vitek 2 CLSI FDA Other Not listed Listed a. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2.
2 Categorical and Quantitative Accuracy Analyses Overall Categorical Accuracy (CA) for DD and MIC methods Table 2 lists the CA of both major AST testing groups (DD and commercial MIC devices) for the 25 mosttested antimicrobial agents. These tested drugs had 100 reported categorical results with the greatest number of responses for ampicillin (1,044), trimethoprim-sulfamethoxazole (TMP-SMX; 1,039), nitrofurantoin (1,027), gentamicin (1,023), ciprofloxacin (984) and cefazolin (953). Laboratory categorical responses for DD users (90 TMP-SMX values) were greatly outnumbered by commercial MIC test users (949 TMP-SMX values; greatest number for gentamicin at 967 results). Approximately 91.5% of participating laboratories utilized a MIC-based system with only 8.5% using DD; 2 see Table 2. Table 2. Categorical accuracy (CA) for DD and MIC methods 1, 2 when testing UR-01 (2017), an E. coli quality control (QC) organism (ATCC 25922). a Antimicrobial agent Expected No. tests (% CA) for: b category a DD method MIC method Amikacin Susceptible 10 (100.0) 440 (99.8) Amoxicillin-Clavulanate Susceptible 43 (97.7) 489 (99.4) Ampicillin Susceptible 81 (95.1) 963 (98.7) Ampicillin-Sulbactam Susceptible 10 (100.0) 780 (99.5) Aztreonam Susceptible 2 (100.0) 382 (99.2) Cefazolin Susceptible 38 (86.8) 915 (99.2) Cefepime Susceptible 5 (100.0) 705 (99.3) Cefotaxime Susceptible 3 (100.0) 319 (99.1) Cefoxitin Susceptible 5 (80.0) 350 (99.1) Ceftazidime Susceptible 12 (100.0) 629 (99.7) Ceftriaxone Susceptible 41 (100.0) 839 (99.8) Cefuroxime Susceptible 11 (81.8) 419 (98.8) Ciprofloxacin Susceptible 84 (100.0) 900 (99.4) Ertapenem Susceptible 4 (100.0) 586 (99.3) Gentamicin Susceptible 56 (100.0) 967 (99.8) Imipenem Susceptible 13 (100.0) 577 (99.1) Levofloxacin Susceptible 30 (100.0) 896 (99.8) Meropenem Susceptible 1 (100.0) 406 (99.3) Nitrofurantoin Susceptible 89 (98.9) 938 (99.7) Piperacillin-Tazobactam Susceptible 10 (100.0) 798 (99.4) Tetracycline Susceptible 35 (100.0) 418 (99.5) Ticarcillin-Clavulanate Susceptible 3 (100.0) 121 (100.0) TMP-SMX Susceptible 90 (98.9) 949 (99.9) Tobramycin Susceptible 11 (100.0) 747 (99.9) Trimethoprim Susceptible 7 (100.0) 105 (99.0) a. E. coli ATCC is a pan-susceptible QC strain. 3 b. CA determined from approximately 90 and 967 participants using DD and MIC methods, respectively; see gentamicin and trimethoprim-sulfamethoxazole (TMP-SMX) data.
3 The graded CA for the DD method was 97.8% (2.2% false-resistant or intermediate errors). The lowest CA among drugs tested by DD was for three cephalosporins (cefazolin [86.8%], cefoxitin [80.0%], cefuroxime [81.8%]), each having a smaller sample size of 5 to 38 results. In contrast, the MIC method CA was 99.5% overall, ranging from 98.7% (ampicillin) to 100.0% (ticarcillin-clavulanate); falsenonsusceptible results were quite rare for TMP-SMX (0.1%), nitrofurantoin (0.3%), aminoglycosides ( %) and the fluoroquinolones ( %). Several antimicrobials of potential clinical utility for UTI therapy were reported by a small number (14-78) of laboratories. Cefixime (17 responses), cefotetan (78), cefpodoxime (25), doripenem (44), nalidixic acid (14) and norfloxacin (32) were tested with excellent CA rates. The reporting of inappropriate drugs for this pathogen and/or infection site is considered unacceptable. These occurrences included: azithromycin (three results), chloramphenicol (one), clarithromycin (one), colistin (one), erythromycin (one), moxifloxacin (12), penicillin (three) and vancomycin (two). Some recently FDA-approved antimicrobials having expanded activity versus the Enterobacteriaceae and an UTI clinical indication should be considered for AST reporting, such as ceftazidime-avibactam and ceftolozane-tazobactam. Only three participants among the more than 1,100 laboratories reported ceftolozane-tazobactam MIC results. CA and QA Analyses of the DD method 2 Table 3 lists the DD zones of inhibition for the 18 drugs most reported on the supplemental quantitative result form. CA among these tallied antimicrobials was 97.3% (97.8% overall; Table 2) and the median zone diameter in mm for each drugs was within the published QC range published in CLSI 100-S27. 3 However, the QA results (% of zones within the published QC guidances) were compromised at only 89.3%. The antimicrobials having the highest rates of "out-of control" results were: amoxicillinclavulanate (28.6%), imipenem (20.0%), cefazolin and tetracycline (18.7%) and ampicillin-sulbactam (16.7%). A total of 660 zones were forwarded by DD users for these analyses.
4 Table 3. Categorical (CA) and quantitative accuracy (QA) of the Kirby-Bauer disk diffusion (DD) method 2 when testing UR-01, a simulated UTI sample containing E. coli ATCC 25922, the commonly used quality control (QC) organism. Antimicrobial Breakpoint Reference QC Median Acceptable DD results (%) tested zone (mm) zone range (mm) zone (mm) CA a QA b Amikacin Amoxicillin-Clavulanate Ampicillin Ampicillin-Sulbactam Cefazolin Cefepime Ceftazidime Ceftriaxone Ciprofloxacin Gentamicin Imipenem Levofloxacin Meropenem Nitrofurantoin Piperacillin-Tazobactam Tetracycline Tobramycin TMP-SMX c a. Graded categorical DD response (susceptible) for listed agents that ranged from only 1 test (meropenem) to 90 results (TMP-SMX). b. Acceptable quantitative (inhibiting zone diameter) results within published QC ranges. 3 c. TMP-SMX = Trimethoprim-Sulfamethoxazole. CA and QA Analyses of the BD Phoenix MIC Device Three commercial MIC devices were tabulated separately (Tables 4-6), each having enough results to calculate both CA and QA (compared to published MIC QC ranges) rates. 3 Table 4 lists the BD Phoenix results (2.8% of MIC reporting sites) for the 18 antimicrobial agents that allowed comparisons of the most reported MIC to the breakpoint criteria and reference MIC QC range, and to calculate the CA and QA.
5 Table 4. Categorical (CA) and quantitative accuracy (QA) of the BD Phoenix MIC device when testing UR-01, a simulated UTI sample containing E. coli ATCC 25922, the commonly used quality control (QC) organism. 3 Antimicrobial tested Breakpoint MIC (µg/ml) Reference MIC QC range (µg/ml) Most reported MIC (%) Acceptable MIC result (%) CA a QA b Amikacin (100) Amoxicillin-Clavulanate 8/4 2/1-8/4 4/2 (75) Ampicillin (100) Ampicillin-Sulbactam 8/4 2/1-8/4 4/2 (100) Cefazolin (75) Cefepime (100) Ceftazidime (88) Ceftriaxone (80) Ciprofloxacin (100) Gentamicin (50) Imipenem (100) Levofloxacin (100) Meropenem (60) Nitrofurantoin (100) Piperacillin-Tazobactam 16/4 1/4-4/4 2/4 (70) Tetracycline (50) Tobramycin (100) TMP-SMX c 2/38 0.5/ /9.5 (100) a. Graded categorical MIC response (susceptible) for listed agents across all tabulated MIC testing devices. b. Acceptable quantitative results (MIC in µg/ml) within published QC range for this brand of commercial MIC device. 3 c. TMP-SMX = Trimethoprim-Sulfamethoxazole. The CA rate across these listed agents was 99.5%, the same as for all reported antimicrobials (Table 2). When the reported BD Phoenix MIC results were compared to the QC range of the E. coli ATCC range 3 for each drug, two concerns were observed: 1) the lowest reported MIC was not within the published QC range 3 or 2) the most reported MIC value was at the upper limit of the QC range. Such results do not allow this commonly used QC strain to be routinely useful for one-half of the 18 drugs and with four additional drugs, only the highest MIC in the QC range was tested; thus requiring the testing of additional QC organisms to assure QA of this test device. The QA for BD Phoenix using this QC strain could only be calculated at 56.0% (range, %) due to the limited number of MIC dilutions reported by this device against the monitored, commonly tested agents (Table 4). CA and QA Analyses of the MicroScan MIC System Table 5 lists the MicroScan device results (used by 43.6% of MIC reporting sites) for the 18 tabulated antimicrobials. When comparing the most reported MIC results for each drug, the dominant MIC was a
6 concentration less than or equal to the published susceptible breakpoint (example, ampicillin at 8 µg/ml). This occurred at 90% for 11 of 18 drugs. For ceftriaxone, the most reported MIC was 8 µg/ml, three log2 dilution steps greater than the current breakpoint published by several organizations 3-5 and the USA- FDA. CA (99.5%) for MicroScan was acceptable, but the QA analysis was nearly impossible to calculate because the reported MIC results were generally well above the published QC range for each drug, e.g. 15 of 18 drugs assessed. 3 The remaining three antimicrobials (amoxicillin-clavulanate, ampicillin, ampicillin-sulbactam) had the reported MIC at the upper limit of the MIC QC range (Table 5). The overall QA for the 18 drugs was only 19.1%. Table 5. Categorical (CA) and quantitative accuracy (QA) of the MicroScan MIC device when testing UR-01, a simulated UTI sample containing E. coli ATCC 25922, the commonly used quality control (QC) organism. 3 Antimicrobial tested Breakpoint MIC (µg/ml) Reference MIC QC range (µg/ml) Most reported MIC (%) Acceptable MIC result (%) CA a QA b Amikacin (98) Amoxicillin-Clavulanate 8/4 2/1-8/4 8/4 (94) Ampicillin (96) Ampicillin-Sulbactam 8/4 2/1-8/4 8/4 (92) Cefazolin (69) Cefepime (52) Ceftazidime (90) Ceftriaxone (60) Ciprofloxacin (97) Gentamicin (82) Imipenem (68) Levofloxacin (95) Meropenem (66) Nitrofurantoin (99) Piperacillin-Tazobactam 16/4 1/4-4/4 16/4 (95) Tetracycline (98) Tobramycin (93) TMP-SMX c 2/38 0.5/9.5 2/38 (95) a. Graded categorical MIC response (susceptible) for listed agents across all tabulated MIC testing devices. b. Acceptable quantitative results (MIC in µg/ml) within published QC range for this brand of commercial MIC device. 3 c. TMP-SMX = Trimethoprim-Sulfamethoxazole. Of additional concern, two cefazolin MIC results were reported as either 2 or 8 µg/ml for this UTI sample. This implies use of differing device products with acceptable and unacceptable QA for this QC strain. Application of these products by survey participants should follow manufacturer QC instructions as
7 well as to assure QA with QC organisms having MIC values within published ranges. 3, 4 Furthermore, refer to current breakpoint criteria tables, to interpret the cefazolin MIC results when testing UTI isolates ( 16 µg/ml as susceptible and as a surrogate predictor for selected oral cephalosporins). 3-5 The oral cephalosporins predicted as active by the susceptibility to cefazolin are: cefaclor, cefdinir, cefpodoxime, cefprozil, cefuroxime, cephalexin and loracarbef. 3 CA and QA Analyses of the Vitek 2 MIC System Table 6 presents the Vitek 2 device results (used by 53.6% of MIC reporting sites) for the 18 tabulated antimicrobial agents. MIC results from this product are calculated from testing several drug concentrations and reported for a validated MIC range for each agent. The most reported calculated MIC values are found in Table 6, and are usually at the lowest extreme of the calculated MIC range but generally extends below the published breakpoints. 3-5 Table 6. Categorical (CA) and quantitative accuracy (QA) of the Vitek 2 MIC device when testing UR-01, a simulated UTI sample containing E. coli ATCC 25922, the commonly used quality control (QC) organism. 3 Antimicrobial Breakpoint Reference MIC Most reported Acceptable MIC result (%) tested MIC (µg/ml) QC range (µg/ml) MIC (%) CA a QA b Amikacin (97) Amoxicillin-Clavulanate 8/4 2/1-8/4 4/2 (75) Ampicillin (84) Ampicillin-Sulbactam 8/4 2/1-8/4 2/1 (64) Cefazolin (100) Cefepime (99) Ceftazidime (100) Ceftriaxone (100) Ciprofloxacin (99) Gentamicin (99) Imipenem (99) Levofloxacin (99) Meropenem (100) Nitrofurantoin (99) Piperacillin-Tazobactam 16/4 1/4-4/4 4/4 (99) Tetracycline (100) Tobramycin (99) TMP-SMX c 2/38 0.5/9.5 1/19 (98) a. Graded categorical MIC response (susceptible) for listed agents across all tabulated MIC testing devices. b. Acceptable quantitative results (MIC in µg/ml) within published QC range for this brand of commercial MIC device. 3 c. TMP-SMX = Trimethoprim-Sulfamethoxazole.
8 This device produced more MIC results that could be assessed for QA versus the E. coli ATCC QC strain (Table 6). 3 Where MIC results could be evaluated for QA, % of MIC values were within the QC range (11 of 18 drugs). However, and like other MIC devices, Vitek 2 often does not extend the calculated MIC dilution range significantly below the published breakpoint concentration. 3 The overall QA for Vitek 2 versus the 18 drugs was 60.9% (MicroScan at 19.1%; BD Phoenix at 56.0%), and the DD method was 89.3%. Major Findings and Points of Concern from Analysis of this Sample (UR-01, 2017) Major Findings for E. coli ATCC UTI Sample Over 1,100 laboratories participated in this survey, approximately 40% forwarding quantitative AST results (MICs and zone diameters) Commercial MIC-based devices (Vitek 2 > MicroScan > BD Phoenix) dominated AST use at >90.0% among 1,610 potentially gradable responses. Interpretive breakpoint criteria applied to AST results were: CLSI (66.2%) > USA-FDA (19%) > others. CA results for 25 drugs were: DD (97.8% correct) and all commercial MIC devices (99.5%). QA Findings (% of results within published CLSI QC ranges) For DD method the QA was at 89.3%, highest "out-of-control" rates for amoxicillin-clavulanate and some other β-lactams. For BD Phoenix device the QA was at 56.0% For MicroScan products the QA was only 19.1% For Vitek 2 system the QA was 60.9% Points of Concern DD QA was below 90% overall Commercial MIC method products rarely or do not directly test/calculate MIC endpoints in a dilution range were the E. coli ATCC can be used as an effective QC strain. This fact limits precision use of MIC results to guide clinical therapy (dosing and TDM) via evolving "Antibiotic Stewardship" programs. Some results forwarded by participating laboratories imply that category breakpoint interpretations are not current with regulatory or other breakpoint publications. 3-5
9 Recommendations Correct/re-evaluate any test procedure where unacceptable categorical grades were received. Re-evaluate AST QC procedures to assure that QC strains are routinely tested to provide measures of QA for each antimicrobial, not just a CA metric. Assure that current category interpretive breakpoints are being applied locally and/or via utilized commercial AST product software. 3-5 References 1. Clinical and Laboratory Standards Institute M07-A10. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard- tenth edition. Wayne, PA. CLSI, Clinical and Laboratory Standards Institute M02-A12. Performance standards for antimicrobial disk susceptibility tests; Twelfth Edition. Wayne, PA. CLSI, Clinical and Laboratory Standards Institute M100-S27. Performance standards for antimicrobial susceptibility testing: 27th informational supplement. Wayne, PA. CLSI, EUCAST. Breakpoint tables for interpretation of MICs and zone diameters. Version 7.0, January Available at Accessed January USCAST. Breakpoint tables for interpretations of MICs and Zone Diameters, Version 3.0, January Available at Accessed March 2017.
Background and Plan of Analysis
ENTEROCOCCI Background and Plan of Analysis UR-11 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony count, to perform the identification
More informationEUCAST recommended strains for internal quality control
EUCAST recommended strains for internal quality control Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus influenzae ATCC 59 ATCC
More informationRoutine internal quality control as recommended by EUCAST Version 3.1, valid from
Routine internal quality control as recommended by EUCAST Version.1, valid from 01-01-01 Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The
More informationCompliance of manufacturers of AST materials and devices with EUCAST guidelines
Compliance of manufacturers of AST materials and devices with EUCAST guidelines Data are based on questionnaires to manufacturers of materials and devices for antimicrobial susceptibility testing. The
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST Version 8.0, valid from 018-01-01
More informationSuggestions for appropriate agents to include in routine antimicrobial susceptibility testing
Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory
More informationCompliance of manufacturers of AST materials and devices with EUCAST guidelines
Compliance of manufacturers of AST materials and devices with EUCAST guidelines Data are based on questionnaires to manufacturers of materials and devices for antimicrobial susceptibility testing. The
More informationJanuary 2014 Vol. 34 No. 1
January 2014 Vol. 34 No. 1. and Minimal Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) roth dilution: cation-adjusted Mueller-Hinton
More informationAntimicrobial Susceptibility Testing: Advanced Course
Antimicrobial Susceptibility Testing: Advanced Course Cascade Reporting Cascade Reporting I. Selecting Antimicrobial Agents for Testing and Reporting Selection of the most appropriate antimicrobials to
More information2016 Antibiotic Susceptibility Report
Fairview Northland Medical Center and Elk River, Milaca, Princeton and Zimmerman Clinics 2016 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2016 Gram-Negative Non-Urine The number of isolates
More informationجداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی
جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی ویرایش دوم بر اساس ed., 2017 CLSI M100 27 th تابستان ۶۹۳۱ تهیه
More informationWhat s new in EUCAST methods?
What s new in EUCAST methods? Derek Brown EUCAST Scientific Secretary Interactive question 1 MIC determination MH-F broth for broth microdilution testing of fastidious microorganisms Gradient MIC tests
More informationJanuary 2014 Vol. 34 No. 1
January 2014 Vol. 34 No. 1. and Minimum Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) Broth dilution: cation-adjusted Mueller-Hinton
More informationAntimicrobial Susceptibility Testing: The Basics
Antimicrobial Susceptibility Testing: The Basics Susan E. Sharp, Ph.D., DABMM, FAAM Director, Airport Way Regional Laboratory Director, Regional Microbiology and Molecular Infectious Diseases Laboratories
More information2015 Antibiotic Susceptibility Report
Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzenza Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens
More information56 Clinical and Laboratory Standards Institute. All rights reserved.
Table 2C 56 Clinical and Laboratory Standards Institute. All rights reserved. Table 2C. Zone Diameter and Minimal Inhibitory Concentration Breakpoints for Testing Conditions Medium: Inoculum: diffusion:
More informationAMR Industry Alliance Antibiotic Discharge Targets
AMR Industry Alliance Antibiotic Discharge Targets List of Predicted No-Effect Concentrations (PNECs) The members of the AMR Industry Alliance have developed a unified approach to establishing discharge
More informationHelp with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST
Help with moving disc diffusion methods from BSAC to EUCAST This document sets out the main differences between the BSAC and EUCAST disc diffusion methods with specific emphasis on preparation prior to
More informationUnderstanding the Hospital Antibiogram
Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital
More informationThe Basics: Using CLSI Antimicrobial Susceptibility Testing Standards
The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards Janet A. Hindler, MCLS, MT(ASCP) UCLA Health System Los Angeles, California, USA jhindler@ucla.edu 1 Learning Objectives Describe information
More informationPerformance Information. Vet use only
Performance Information Vet use only Performance of plates read manually was measured in three sites. Each centre tested Enterobacteriaceae, streptococci, staphylococci and pseudomonas-like organisms.
More information21 st Expert Committee on Selection and Use of Essential Medicines Peer Review Report Antibiotics Review
(1) Have all important studies/evidence of which you are aware been included in the application? Yes No Please provide brief comments on any relevant studies that have not been included: (2) For each of
More information1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient
1 Chapter 79, Self-Assessment Questions 1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient with normal renal function is: A. Trimethoprim-sulfamethoxazole B. Cefuroxime
More informationSMART WORKFLOW SOLUTIONS Introducing DxM MicroScan WalkAway System* ...
SMART WORKFLOW SOLUTIONS Introducing DxM MicroScan WalkAway System* The next-generation MicroScan WalkAway System combines proven technology and reliability with enhanced ease-of-use features to streamline
More informationTHE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS
THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS Stefanie Desmet University Hospitals Leuven Laboratory medicine microbiology stefanie.desmet@uzleuven.be
More informationIntrinsic, implied and default resistance
Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been
More informationAntibiotic Updates: Part II
Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More informationGENERAL NOTES: 2016 site of infection type of organism location of the patient
GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered
More informationStreptococcus pneumoniae. Oxacillin 1 µg as screen for beta-lactam resistance
Streptococcus pneumoniae Oxacillin µg as screen for beta-lactam resistance Version 6. June Streptococcus pneumoniae and zone diameter correlates The following histograms present inhibition zone diameter
More informationESBL Producers An Increasing Problem: An Overview Of An Underrated Threat
ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat Hicham Ezzat Professor of Microbiology and Immunology Cairo University Introduction 1 Since the 1980s there have been dramatic
More informationCAP Laboratory Improvement Programs. Performance Accuracy of Antibacterial and Antifungal Susceptibility Test Methods
CAP Laboratory Improvement Programs Performance Accuracy of Antibacterial and Antifungal usceptibility Test Methods Report From the College of American Pathologists Microbiology urveys Program (001 003)
More informationAvailable online at ISSN No:
Available online at www.ijmrhs.com ISSN No: 2319-5886 International Journal of Medical Research & Health Sciences, 2017, 6(4): 36-42 Comparative Evaluation of In-Vitro Doripenem Susceptibility with Other
More informationIMPORTANCE OF GLOBAL HARMONIZATION OF ANTIMICROBIAL SUSCEPTIBILITY TESTING IN CANADA FOR DEFINING ANTIMICROBIAL RESISTANCE
IMPORTANCE OF GLOBAL HARMONIZATION OF ANTIMICROBIAL SUSCEPTIBILITY TESTING IN CANADA FOR DEFINING ANTIMICROBIAL RESISTANCE Robert P. Rennie Professor Emeritus Laboratory Medicine and Pathology University
More informationConcise Antibiogram Toolkit Background
Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions
More informationEUCAST-and CLSI potency NEO-SENSITABS
EUCASTand CLSI potency NEOSENSITABS Neo Sensitabs Page 1 / 6 Document: 6.2.0 Fastidious organisms EUCAST Interpretation zones and MIC breakpoints according to recommendations by the "Comité de l'antibiogramme
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIX NUMBER 3 November 2014 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Marti Roe SM MLS (ASCP), Sarah Parker MD, Jason Child PharmD, and Samuel R.
More informationVersion 1.01 (01/10/2016)
CHN58: ANTIMICROBIAL SUSCEPTIBILITY TESTING (CLSI) 1.0 PURPOSE / INTRODUCTION: 1.1 Introduction Antimicrobial susceptibility tests are performed in order to determine whether a pathogen is likely to be
More informationMain objectives of the EURL EQAS s
EQAS Enterococci, Staphylococci and E. coli EURL workshop, April, 11 Lourdes García Migura Main objectives of the EURL EQAS s To improve the comparability of antimicrobial susceptibility testing (AST)
More informationMethod Preferences and Test Accuracy of Antimicrobial Susceptibility Testing
Method Preferences and Test Accuracy of Antimicrobial Susceptibility Testing Updates From the College of American Pathologists Microbiology Surveys Program (2000) Ronald N. Jones, MD; for the College of
More informationAntibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting
Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria
More informationEducating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges
Educating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges Janet Hindler, MCLS MT(ASCP) UCLA Medical Center jhindler@ucla.edu also working as a consultant with the Association
More informationPROTOCOL for serotyping and antimicrobial susceptibility testing of Salmonella test strains
PROTOCOL for serotyping and antimicrobial susceptibility testing of Salmonella test strains 1 INTRODUCTION... 1 2 OBJECTIVES... 2 3 OUTLINE OF THE EQAS 2017... 2 3.1 Shipping, receipt and storage of strains...
More informationNational Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults
National Clinical Guideline Centre Antibiotic classifications Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults Clinical guideline 191 Appendix N 3 December 2014
More informationPerichondritis: Source: UpToDate Ciprofloxacin 10 mg/kg/dose PO (max 500 mg/dose) BID Inpatient: Ceftazidime 50 mg/kg/dose q8 hours IV
Empiric Antibiotics for Pediatric Infections Seen in ED NOTE: Choice of empiric antibiotic therapy must take into account local pathogen frequency and resistance patterns, individual patient characteristics,
More informationChildrens Hospital Antibiogram for 2012 (Based on data from 2011)
Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical
More informationRecommendations to take it forward!
Capacity Building and Strengthening of Hospital Infection Control to detect and prevent antimicrobial resistance in India AIIMS-ICMR-CDC EQAS Recommendations to take it forward! Top regional diagnostic
More informationThis document is protected by international copyright laws.
Table 2C Table 2C. and s for Product Name: Infobase 2010 - Release Date: February 2010 60 Clinical and Laboratory Standards Institute. All rights reserved. Testing Conditions Medium: diffusion: MHA Broth
More informationBritish Society for Antimicrobial Chemotherapy
British Society for Antimicrobial Chemotherapy BSAC to actively support the EUCAST Disc Diffusion Method for Antimicrobial Susceptibility Testing in preference to the current BSAC Disc Diffusion Method
More informationBrief reports. Heat stability of the antimicrobial activity of sixty-two antibacterial agents
Journal of Antimicrobial Chemotherapy (5) 35, -5 Brief reports Heat stability of the antimicrobial activity of sixty-two antibacterial agents Walter H. Traub and Birgit Leonhard Institut fur Medizinische
More informationHelen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory
METHODS USED IN NEW ZEALAND DIAGNOSTIC LABORATORIES TO IDENTIFY AND REPORT EXTENDED-SPECTRUM β-lactamase- PRODUCING ENTEROBACTERIACEAE by Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory
More informationMercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016
Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate
More informationBritish Society for Antimicrobial Chemotherapy
British Society for Antimicrobial Chemotherapy Standing Committee on Susceptibility Testing Version 13.0, 10-06-2014 Content Page Additional information Changes in version 13 2 Suggestions for appropriate
More informationShould we test Clostridium difficile for antimicrobial resistance? by author
Should we test Clostridium difficile for antimicrobial resistance? Paola Mastrantonio Department of Infectious Diseases Istituto Superiore di Sanità, Rome,Italy Clostridium difficile infection (CDI) (first
More informationTo view an archived recording of this presentation please click the following link:
To view an archived recording of this presentation please click the following link: http://pho.adobeconnect.com/p3n7qn7y5kg/ Please scroll down this file to view a copy of the slides from the session.
More informationMark Your Calendars Now! Next Event Ships: September 14, 2015
www.wslhpt.org 2601 Agriculture Drive Madison, WI 53718 (800) 462-5261 (608) 265-1111 Shipment Date: June 15, 2015 Questions or comments should be directed to Amanda Weiss at 800-462-5261 x51 or amanda.weiss@slh.wisc.edu.
More informationInterpreting Microbiology reports for better Clinical Decisions Interpreting Antibiogrammes
Interpreting Microbiology reports for better Clinical Decisions Interpreting Antibiogrammes Prof C. Wattal Hon. Sr. Consultant & Chairman Dept. of Clinical Microbiology Sir Ganga Ram Hospital New Delhi
More informationPrevalence of Extended Spectrum Beta- Lactamase Producers among Various Clinical Samples in a Tertiary Care Hospital: Kurnool District, India
International Journal of Current Microbiology and Applied Sciences ISSN: 319-77 Volume Number (17) pp. 57-3 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/1.5/ijcmas.17..31
More informationMichael Hombach*, Guido V. Bloemberg and Erik C. Böttger
J Antimicrob Chemother 2012; 67: 622 632 doi:10.1093/jac/dkr524 Advance Access publication 13 December 2011 Effects of clinical breakpoint changes in CLSI guidelines 2010/2011 and EUCAST guidelines 2011
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #116 (NQF 0058): Avoidance of Antibiotic Treatment in Adults With Acute Bronchitis National Quality Strategy Domain: Efficiency and Cost Reduction 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY
More information1 INTRODUCTION OBJECTIVES OUTLINE OF THE SALM/CAMP EQAS
PROTOCOL For antimicrobial susceptibility testing of Salmonella, Campylobacter and optional genotypic characterisation of AmpC-, ESBL- and carbapenemase-producing test strains 1 INTRODUCTION... 1 2 OBJECTIVES...
More informationESCMID Online Lecture Library. by author
Quality Assurance of antimicrobial susceptibility testing Derek Brown EUCAST Scientific Secretary ESCMID Postgraduate Education Course, Linz, 17 September 2014 Quality Assurance The total process by which
More informationAntibiotic Susceptibility of Common Bacterial Pathogens in Canine Urinary Tract Infections
Vol.1 No.2 Oct-Dec 2013 ISSN : 2321-6387 Antibiotic Susceptibility of Common Bacterial Pathogens in Canine Urinary Tract Infections S. Yogeshpriya*, Usha N.Pillai, S. Ajithkumar and N. Madhavan Unny Department
More informationBactiReg3 Event Notes Module Page(s) 4-9 (TUL) Page 1 of 21
www.wslhpt.org 2601 Agriculture Drive Madison, WI 53718 (800) 462-5261 (608) 265-1111 2015-BactiR Reg3 Shipment Date: September 14, 2015 Questions or comments should be directed to Amanda Weiss at 800-462-5261
More informationAntimicrobial susceptibility of Salmonella, 2016
susceptibility of Salmonella, 06 Hospital and community laboratories are requested to refer all Salmonella isolated from human salmonellosis cases to ESR for serotyping and the laboratory-based surveillance
More informationApproach to pediatric Antibiotics
Approach to pediatric Antibiotics Gassem Gohal FAAP FRCPC Assistant professor of Pediatrics objectives To be familiar with common pediatric antibiotics o Classification o Action o Adverse effect To discus
More informationDetecting / Reporting Resistance in Nonfastidious GNR Part #2. Janet A. Hindler, MCLS MT(ASCP)
Detecting / Reporting Resistance in Nonfastidious GNR Part #2 Janet A. Hindler, MCLS MT(ASCP) Methods Described in CLSI M100-S21 for Testing non-enterobacteriaceae Organism Disk Diffusion MIC P. aeruginosa
More informationMicroScan Microbiology Systems MORE CHOICES MORE ANSWERS. MicroScan GRAM NEGATIVE AND GRAM POSITIVE PANELS
MicroScan Microbiology Systems MORE CHOICES MORE ANSWERS MicroScan GRAM NEGATIVE AND GRAM POSITIVE PANELS LABORATORIES ON THE FRONT LINE From the National Action Plan for Combating Antibiotic Resistant
More informationANTIMICROBIAL SUSCEPTIBILITY TESTING ESBL-PRODUCING ENTEROBACTERIACEAE (E. coli ST131) WITH MDR ANTIBIOGRAMS
(E. coli ST131) WITH MDR ANTIBIOGRAMS Sample ES-01 (2016) was a simulated urinary tract culture for organism identification and susceptibility testing using laboratories routinely applied methods. 1-6
More information2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine
2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXXII NUMBER 6 September 2017 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Stacey Hamilton MT SM (ASCP), Samuel Dominguez MD PhD, Sarah Parker MD, and
More informationIntroduction. Antimicrobial Usage ESPAUR 2014 Previous data validation Quality Premiums Draft tool CDDFT Experience.
Secondary Care Data Validation: What do commissioners need to know? Stuart Brown Healthcare Acquired Infection and Antimicrobial Resistance Project Lead NHS England March 2014 Introduction Antimicrobial
More informationAntimicrobial Susceptibility Patterns
Antimicrobial Susceptibility Patterns KNH SURGERY Department Masika M.M. Department of Medical Microbiology, UoN Medicines & Therapeutics Committee, KNH Outline Methodology Overall KNH data Surgery department
More informationREVOLUTIONARY. MMinimum. BBiofilm EEradication Concentration. inimizing WE HAVE FOUND THE ANSWER.
REVOLUTIONARY. Are recurrent bacterial infections a frustration in your practice? WE HAVE FOUND THE ANSWER. MMinimum inimizing BBiofilm EEradication C oncentration Concentration www.becscreen.com WHY BIOFILM
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationAntibiotic Abyss. Discussion Points. MRSA Treatment Guidelines
Antibiotic Abyss Fredrick M. Abrahamian, D.O., FACEP, FIDSA Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical Center Sylmar, California
More informationAntimicrobial susceptibility
Antimicrobial susceptibility PATTERNS Microbiology Department Canterbury ealth Laboratories and Clinical Pharmacology Department Canterbury District ealth Board March 2011 Contents Preface... Page 1 ANTIMICROBIAL
More informationThere are two international organisations that set up guidelines and interpretive breakpoints for bacteriology and susceptibility
ANTIMICROBIAL SUSCEPTIBILITY TESTING ON MILK SAMPLES Method and guidelines There are two international organisations that set up guidelines and interpretive breakpoints for bacteriology and susceptibility
More informationPlease distribute a copy of this information to each provider in your organization.
HEALTH ADVISORY TO: Physicians and other Healthcare Providers Please distribute a copy of this information to each provider in your organization. Questions regarding this information may be directed to
More informationDefining Resistance and Susceptibility: What S, I, and R Mean to You
Defining Resistance and Susceptibility: What S, I, and R Mean to You Michael D. Apley, DVM, PhD, DACVCP Department of Clinical Sciences College of Veterinary Medicine Kansas State University Susceptible
More informationPrinciples of Infectious Disease. Dr. Ezra Levy CSUHS PA Program
Principles of Infectious Disease Dr. Ezra Levy CSUHS PA Program I. Microbiology (1) morphology (e.g., cocci, bacilli) (2) growth characteristics (e.g., aerobic vs anaerobic) (3) other qualities (e.g.,
More informationTaiwan Surveillance of Antimicrobial Resistance (TSAR)
Taiwan Surveillance of Antimicrobial Resistance (TSAR) 2009 MIRL Symposium July 17, 2009 Tsai-Ling Yang Lauderdale ( ) Microbial Infections Reference Laboratory (MIRL) Division of Infectious Diseases,
More informationAntimicrobial Update. Alison MacDonald Area Antimicrobial Pharmacist NHS Highland April 2018
Antimicrobial Update Alison MacDonald Area Antimicrobial Pharmacist NHS Highland alisonc.macdonald@nhs.net April 2018 Starter Questions Setting the scene... What if antibiotics were no longer effective?
More informationUNDERSTANDING YOUR DATA: THE ANTIBIOGRAM
UNDERSTANDING YOUR DATA: THE ANTIBIOGRAM April Abbott, PhD, D(ABMM) Deaconess Health System Evansville, IN April.Abbott@Deaconess.com Special thanks to Dr. Shelley Miller for UCLA data WHAT WE WILL COVER
More informationInt.J.Curr.Microbiol.App.Sci (2017) 6(11):
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 11 (2017) pp. 2293-2299 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.611.272
More informationAntimicrobial Stewardship Strategy: Antibiograms
Antimicrobial Stewardship Strategy: Antibiograms A summary of the cumulative susceptibility of bacterial isolates to formulary antibiotics in a given institution or region. Its main functions are to guide
More informationEinheit für pädiatrische Infektiologie Antibiotics - what, why, when and how?
Einheit für pädiatrische Infektiologie Antibiotics - what, why, when and how? Andrea Duppenthaler andrea.duppenthaler@insel.ch Limping patient local pain swelling tenderness warmth fever acute Osteomyelitis
More informationMeasuring Antibiotic Use in NHSN
Measuring Antibiotic Use in NHSN Jonathan R. Edwards, MStat. Research Mathematical Statistician Division of Healthcare Quality Promotion National Center for Emerging and Zoonotic Infectious Diseases SHEA
More informationComparative Assessment of b-lactamases Produced by Multidrug Resistant Bacteria
Comparative Assessment of b-lactamases Produced by Multidrug Resistant Bacteria Juhee Ahn Department of Medical Biomaterials Engineering Kangwon National University October 23, 27 Antibiotic Development
More informationEXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING
EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING CHN61: EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING 1.1 Introduction A common mechanism of bacterial resistance to beta-lactam antibiotics is the production
More informationBSAC standardized disc susceptibility testing method (version 8)
Journal of Antimicrobial Chemotherapy (2009) 64, 454 489 doi:10.1093/jac/dkp244 Advance Access publication 8 July 2009 BSAC standardized disc susceptibility testing method (version 8) J. M. Andrews* for
More informationFlorida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC
Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC 11/20/2014 1 To describe carbapenem-resistant Enterobacteriaceae. To identify laboratory detection standards for carbapenem-resistant
More informationUpdate on the CLSI Standards for Antimicrobial Susceptibility Testing: What s New with the Gram Positive Organisms?
2 0 1 3 CASES (with answers!) Update on the CLSI Standards for Antimicrobial Susceptibility Testing: What s New with the Gram Positive Organisms? Susan E. Sharp, Ph.D., DABMM, FAAM Director - Regional
More informationAdvanced Practice Education Associates. Antibiotics
Advanced Practice Education Associates Antibiotics Overview Difference between Gram Positive(+), Gram Negative(-) organisms Beta lactam ring, allergies Antimicrobial Spectra of Antibiotic Classes 78 Copyright
More informationJasmine M. Chaitram, 1,2 * Laura A. Jevitt, 1,2 Sara Lary, 1,2 Fred C. Tenover, 1,2 and The WHO Antimicrobial Resistance Group 3,4
JOURNAL OF CLINICAL MICROBIOLOGY, June 2003, p. 2372 2377 Vol. 41, No. 6 0095-1137/03/$08.00 0 DOI: 10.1128/JCM.41.6.2372 2377.2003 The World Health Organization s External Quality Assurance System Proficiency
More informationANTIMICROBIAL SUSCEPTIBILITY DETECTION OF ELEVATED MICs TO PENICILLINS IN β- HAEMOLYTIC STREPTOCOCCI
HAEMOLYTIC STREPTOCOCCI This specimen was designated as a sample from a skin wound that was to be cultured, identified to species level and susceptibility tested [1-3]. The culture contained a Streptococcus
More informationShort Report. R Boot. Keywords: Bacteria, antimicrobial susceptibility testing, quality, diagnostic laboratories, proficiency testing
Short Report Frequent major errors in antimicrobial susceptibility testing of bacterial strains distributed under the Deutsches Krebsforschungszentrum Quality Assurance Program R Boot Former Section of
More informationADC 2016 Report on Bacterial Resistance in Cultures from SEHOS and General Practitioners in Curaçao
ADC 216 Report on Bacterial Resistance in Cultures from SEHOS and General Practitioners in Curaçao Willemstad, November 217 Authors: Radjin Steingrover clinical microbiologist, head dpt. Microbiology ADC
More informationESCMID Online Lecture Library. by author
Expert rules in susceptibility testing EUCAST-ESGARS-EPASG Educational Workshop Linz, 16 19 September, 2014 Dr. Rafael Cantón Hospital Universitario Ramón y Cajal SERVICIO DE MICROBIOLOGÍA Y PARASITOLOGÍA
More informationWhat is new in 2011: Methods and breakpoints in relation to subcommittees and expert groups. by author. Gunnar Kahlmeter, Derek Brown
What is new in 2011: Methods and breakpoints in relation to subcommittees and expert groups Gunnar Kahlmeter, Derek Brown Izmir, February 2011 Anaerobes subcommittee EUCAST Subcommittee on breakpoints
More information